Bezlotoxumab for prevention of recurrent clostridium difficile infection in cancer patients: Report of clinical case

• Autores: B. Rogado Vegas, Julia Sánchez Gundín, David Gómez Gómez, M. Valero Domínguez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 22, Nº. 2, 2020, págs. 114-116
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Bezlotoxumab (human antitoxin monoclonal antibody that binds with high affinity to Clostridium difficile toxin B neutralizing its activity) is an innovative therapy in the prevention of recurrent Clostridium difficile infection (CDI), a growing problem both at hospital level and in the community and with no published data from real-life experience. In the case of oncological patients with chemotherapy (this case), recurrent CDI is especially relevant, as it implies delays in antineoplastic administration affecting the course of the disease. © 2020 Rasgo Editorial S.A.. All rights reserved.